D
Knight Therapeutics Inc.
KHTRF
$3.79
-$0.0965-2.48%
D
Sell
11/13/2023Upgraded
Knight Therapeutics Inc. (KHTRF) was upgraded to D- from E+ on 11/13/2023 due to a significant increase in the growth index, solvency index and volatility index. Operating cash flow increased 1,122.15% from -$1.11M to $11.31M, EBIT increased 946.64% from -$81.9 to $693.4, and earnings per share increased from $0.0126 to $0.0671.
Knight Therapeutics Inc. (KHTRF) was upgraded to D- from E+ on 11/13/2023 due to a significant increase in the growth index, solvency index and volatility index. Operating cash flow increased 1,122.15% from -$1.11M to $11.31M, EBIT increased 946.64% from -$81.9 to $693.4, and earnings per share increased from $0.0126 to $0.0671.
E
Sell
10/10/2023Downgrade
Knight Therapeutics Inc. (KHTRF) was downgraded to E+ from D- on 10/10/2023 due to a decline in the volatility index, total return index and valuation index.
Knight Therapeutics Inc. (KHTRF) was downgraded to E+ from D- on 10/10/2023 due to a decline in the volatility index, total return index and valuation index.
D
Sell
9/25/2023Upgraded
Knight Therapeutics Inc. (KHTRF) was upgraded to D- from E+ on 9/25/2023 due to a noticeable increase in the growth index, volatility index and solvency index. Earnings per share increased from -$0.0296 to $0.0126, total revenue increased 9.59% from $61.07M to $66.92M, and the quick ratio increased from 2.19 to 2.23.
Knight Therapeutics Inc. (KHTRF) was upgraded to D- from E+ on 9/25/2023 due to a noticeable increase in the growth index, volatility index and solvency index. Earnings per share increased from -$0.0296 to $0.0126, total revenue increased 9.59% from $61.07M to $66.92M, and the quick ratio increased from 2.19 to 2.23.
E
Sell
5/22/2023Downgrade
Knight Therapeutics Inc. (KHTRF) was downgraded to E+ from D on 5/22/2023 due to a significant decline in the efficiency index, total return index and volatility index. Total capital declined 0.2% from $667.61M to $666.3M.
Knight Therapeutics Inc. (KHTRF) was downgraded to E+ from D on 5/22/2023 due to a significant decline in the efficiency index, total return index and volatility index. Total capital declined 0.2% from $667.61M to $666.3M.
D
Sell
10/6/2022Downgrade
Knight Therapeutics Inc. (KHTRF) was downgraded to D from D+ on 10/6/2022 due to a decline in the total return index and volatility index.
Knight Therapeutics Inc. (KHTRF) was downgraded to D from D+ on 10/6/2022 due to a decline in the total return index and volatility index.
D
Sell
9/21/2022Upgraded
Knight Therapeutics Inc. (KHTRF) was upgraded to D+ from D on 9/21/2022 due to a noticeable increase in the total return index, volatility index and valuation index.
Knight Therapeutics Inc. (KHTRF) was upgraded to D+ from D on 9/21/2022 due to a noticeable increase in the total return index, volatility index and valuation index.
D
Sell
5/16/2022Downgrade
Knight Therapeutics Inc. (KHTRF) was downgraded to D from D+ on 5/16/2022 due to a significant decline in the valuation index, efficiency index and volatility index. Net income declined 125.42% from -$6.59M to -$14.85M.
Knight Therapeutics Inc. (KHTRF) was downgraded to D from D+ on 5/16/2022 due to a significant decline in the valuation index, efficiency index and volatility index. Net income declined 125.42% from -$6.59M to -$14.85M.
D
Sell
11/15/2021Downgrade
Knight Therapeutics Inc. (KHTRF) was downgraded to D+ from C- on 11/15/2021 due to a large decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.1873 to -$0.0556, net income declined 128.86% from $23.62M to -$6.81M, and operating cash flow declined 18.93% from $10.1M to $8.19M.
Knight Therapeutics Inc. (KHTRF) was downgraded to D+ from C- on 11/15/2021 due to a large decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.1873 to -$0.0556, net income declined 128.86% from $23.62M to -$6.81M, and operating cash flow declined 18.93% from $10.1M to $8.19M.
C
Hold
8/30/2021Upgraded
Knight Therapeutics Inc. (KHTRF) was upgraded to C- from D+ on 8/30/2021 due to an increase in the total return index.
Knight Therapeutics Inc. (KHTRF) was upgraded to C- from D+ on 8/30/2021 due to an increase in the total return index.
D
Sell
8/13/2021Downgrade
Knight Therapeutics Inc. (KHTRF) was downgraded to D+ from C- on 8/13/2021 due to a decline in the volatility index.
Knight Therapeutics Inc. (KHTRF) was downgraded to D+ from C- on 8/13/2021 due to a decline in the volatility index.
C
Hold
8/4/2021Upgraded
Knight Therapeutics Inc. (KHTRF) was upgraded to C- from D+ on 8/4/2021 due to an increase in the volatility index and valuation index.
Knight Therapeutics Inc. (KHTRF) was upgraded to C- from D+ on 8/4/2021 due to an increase in the volatility index and valuation index.
D
Sell
7/8/2021Downgrade
Knight Therapeutics Inc. (KHTRF) was downgraded to D+ from C- on 7/8/2021 due to a decline in the volatility index.
Knight Therapeutics Inc. (KHTRF) was downgraded to D+ from C- on 7/8/2021 due to a decline in the volatility index.
C
Hold
6/22/2021Upgraded
Knight Therapeutics Inc. (KHTRF) was upgraded to C- from D+ on 6/22/2021 due to an increase in the volatility index, valuation index and total return index.
Knight Therapeutics Inc. (KHTRF) was upgraded to C- from D+ on 6/22/2021 due to an increase in the volatility index, valuation index and total return index.
D
Sell
6/3/2021Downgrade
Knight Therapeutics Inc. (KHTRF) was downgraded to D+ from C- on 6/3/2021 due to a decline in the valuation index and volatility index.
Knight Therapeutics Inc. (KHTRF) was downgraded to D+ from C- on 6/3/2021 due to a decline in the valuation index and volatility index.
C
Hold
5/18/2021Upgraded
Knight Therapeutics Inc. (KHTRF) was upgraded to C- from D+ on 5/18/2021 due to an increase in the valuation index, efficiency index and volatility index.
Knight Therapeutics Inc. (KHTRF) was upgraded to C- from D+ on 5/18/2021 due to an increase in the valuation index, efficiency index and volatility index.
D
Sell
5/13/2021Downgrade
Knight Therapeutics Inc. (KHTRF) was downgraded to D+ from C- on 5/13/2021 due to a decline in the volatility index and valuation index.
Knight Therapeutics Inc. (KHTRF) was downgraded to D+ from C- on 5/13/2021 due to a decline in the volatility index and valuation index.
C
Hold
4/14/2021Upgraded
Knight Therapeutics Inc. (KHTRF) was upgraded to C- from D+ on 4/14/2021 due to an increase in the total return index.
Knight Therapeutics Inc. (KHTRF) was upgraded to C- from D+ on 4/14/2021 due to an increase in the total return index.
D
Sell
3/30/2021Downgrade
Knight Therapeutics Inc. (KHTRF) was downgraded to D+ from C- on 3/30/2021 due to a decline in the volatility index and solvency index. Debt to equity increased from 0.05 to 0.06, and the quick ratio declined from 4.66 to 4.23.
Knight Therapeutics Inc. (KHTRF) was downgraded to D+ from C- on 3/30/2021 due to a decline in the volatility index and solvency index. Debt to equity increased from 0.05 to 0.06, and the quick ratio declined from 4.66 to 4.23.
C
Hold
1/20/2021Upgraded
Knight Therapeutics Inc. (KHTRF) was upgraded to C- from D+ on 1/20/2021 due to an increase in the total return index and volatility index.
Knight Therapeutics Inc. (KHTRF) was upgraded to C- from D+ on 1/20/2021 due to an increase in the total return index and volatility index.
D
Sell
1/5/2021Downgrade
Knight Therapeutics Inc. (KHTRF) was downgraded to D+ from C- on 1/5/2021 due to a decline in the volatility index, valuation index and total return index.
Knight Therapeutics Inc. (KHTRF) was downgraded to D+ from C- on 1/5/2021 due to a decline in the volatility index, valuation index and total return index.
C
Hold
12/21/2020Upgraded
Knight Therapeutics Inc. (KHTRF) was upgraded to C- from D+ on 12/21/2020 due to an increase in the volatility index.
Knight Therapeutics Inc. (KHTRF) was upgraded to C- from D+ on 12/21/2020 due to an increase in the volatility index.
D
Sell
12/2/2020Downgrade
Knight Therapeutics Inc. (KHTRF) was downgraded to D+ from C- on 12/2/2020 due to a decline in the total return index and volatility index.
Knight Therapeutics Inc. (KHTRF) was downgraded to D+ from C- on 12/2/2020 due to a decline in the total return index and volatility index.
C
Hold
11/16/2020Upgraded
Knight Therapeutics Inc. (KHTRF) was upgraded to C- from D on 11/16/2020 due to a significant increase in the valuation index, solvency index and growth index. The quick ratio increased from 1.97 to 4.66, debt to equity declined from 0.06 to 0.05, and earnings per share increased from $0.096 to $0.1036.
Knight Therapeutics Inc. (KHTRF) was upgraded to C- from D on 11/16/2020 due to a significant increase in the valuation index, solvency index and growth index. The quick ratio increased from 1.97 to 4.66, debt to equity declined from 0.06 to 0.05, and earnings per share increased from $0.096 to $0.1036.
D
Sell
5/20/2020Downgrade
Knight Therapeutics Inc. (KHTRF) was downgraded to D from D+ on 5/20/2020 due to a large decline in the solvency index, valuation index and growth index. Earnings per share declined from -$0.0163 to -$0.0402, and the quick ratio declined from 10.03 to 1.5.
Knight Therapeutics Inc. (KHTRF) was downgraded to D from D+ on 5/20/2020 due to a large decline in the solvency index, valuation index and growth index. Earnings per share declined from -$0.0163 to -$0.0402, and the quick ratio declined from 10.03 to 1.5.
D
Sell
2/26/2020Downgrade
Knight Therapeutics Inc. (KHTRF) was downgraded to D+ from C- on 2/26/2020 due to a decline in the volatility index, total return index and efficiency index.
Knight Therapeutics Inc. (KHTRF) was downgraded to D+ from C- on 2/26/2020 due to a decline in the volatility index, total return index and efficiency index.
C
Hold
11/14/2019Downgrade
Knight Therapeutics Inc. (KHTRF) was downgraded to C- from C on 11/14/2019 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.0987 to -$0.0163, net income declined 115.82% from $14.17M to -$2.24M, and total capital declined 9.66% from $802.04M to $724.54M.
Knight Therapeutics Inc. (KHTRF) was downgraded to C- from C on 11/14/2019 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.0987 to -$0.0163, net income declined 115.82% from $14.17M to -$2.24M, and total capital declined 9.66% from $802.04M to $724.54M.
C
Hold
8/13/2019Upgraded
Knight Therapeutics Inc. (KHTRF) was upgraded to C from C- on 8/13/2019 due to an increase in the valuation index, efficiency index and solvency index. Net income increased 263.04% from $3.9M to $14.17M, and total capital increased 3.71% from $773.34M to $802.04M.
Knight Therapeutics Inc. (KHTRF) was upgraded to C from C- on 8/13/2019 due to an increase in the valuation index, efficiency index and solvency index. Net income increased 263.04% from $3.9M to $14.17M, and total capital increased 3.71% from $773.34M to $802.04M.
C
Hold
3/29/2019Downgrade
Knight Therapeutics Inc. (KHTRF) was downgraded to C- from C on 3/29/2019 due to a noticeable decline in the volatility index, total return index and solvency index. The quick ratio declined from 42.49 to 41.18.
Knight Therapeutics Inc. (KHTRF) was downgraded to C- from C on 3/29/2019 due to a noticeable decline in the volatility index, total return index and solvency index. The quick ratio declined from 42.49 to 41.18.
C
Hold
8/14/2018Upgraded
Knight Therapeutics Inc. (KHTRF) was upgraded to C from C- on 8/14/2018 due to a noticeable increase in the valuation index, volatility index and growth index.
Knight Therapeutics Inc. (KHTRF) was upgraded to C from C- on 8/14/2018 due to a noticeable increase in the valuation index, volatility index and growth index.
C
Hold
1/23/2018Downgrade
Knight Therapeutics Inc. (KHTRF) was downgraded to C- from C on 1/23/2018 due to a significant decline in the valuation index and volatility index.
Knight Therapeutics Inc. (KHTRF) was downgraded to C- from C on 1/23/2018 due to a significant decline in the valuation index and volatility index.
C
Hold
5/5/2016Upgraded
Knight Therapeutics Inc. (KHTRF) was upgraded to C from C- on 5/5/2016 due to an increase in the efficiency index.
Knight Therapeutics Inc. (KHTRF) was upgraded to C from C- on 5/5/2016 due to an increase in the efficiency index.
C
Hold
2/1/2016Upgraded
Knight Therapeutics Inc. (KHTRF) was upgraded to C- from D+ on 2/1/2016 due to an increase in the growth index, efficiency index and valuation index. EBIT increased 34.12% from -$2.21M to -$2.96M, total capital increased 10.68% from $421.84M to $466.9M, and operating cash flow increased 9.97% from -$677.7 to -$745.3.
Knight Therapeutics Inc. (KHTRF) was upgraded to C- from D+ on 2/1/2016 due to an increase in the growth index, efficiency index and valuation index. EBIT increased 34.12% from -$2.21M to -$2.96M, total capital increased 10.68% from $421.84M to $466.9M, and operating cash flow increased 9.97% from -$677.7 to -$745.3.
D
Sell
11/2/2015Upgraded
Knight Therapeutics Inc. (KHTRF) was upgraded to D+ from D on 11/2/2015 due to an increase in the total return index, valuation index and growth index. Total revenue increased 35.78% from $199.3 to $270.6, and EBIT increased 7.11% from -$2.06M to -$2.21M.
Knight Therapeutics Inc. (KHTRF) was upgraded to D+ from D on 11/2/2015 due to an increase in the total return index, valuation index and growth index. Total revenue increased 35.78% from $199.3 to $270.6, and EBIT increased 7.11% from -$2.06M to -$2.21M.
D
Sell
5/1/2015Upgraded
Knight Therapeutics Inc. (KHTRF) was upgraded to D from D- on 5/1/2015 due to a significant increase in the valuation index, efficiency index and total return index. Net income increased 21,201.03% from $516.7 to $110.06M, and total capital increased 77.45% from $233.09M to $413.61M.
Knight Therapeutics Inc. (KHTRF) was upgraded to D from D- on 5/1/2015 due to a significant increase in the valuation index, efficiency index and total return index. Net income increased 21,201.03% from $516.7 to $110.06M, and total capital increased 77.45% from $233.09M to $413.61M.
D
Sell
1/2/2015Upgraded
Knight Therapeutics Inc. (KHTRF) was upgraded to D- from E+ on 1/2/2015 due to an increase in the volatility index and total return index.
Knight Therapeutics Inc. (KHTRF) was upgraded to D- from E+ on 1/2/2015 due to an increase in the volatility index and total return index.
E
Sell
11/20/2014None
Knight Therapeutics Inc. (KHTRF) was downgraded to E+ from U on 11/20/2014.
Knight Therapeutics Inc. (KHTRF) was downgraded to E+ from U on 11/20/2014.
OTC PK
03/10/2025 10:18AM Eastern
Quotes delayed
